Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04141969 · ClinicalTrials.gov registry record · Phase 2
A Novel Nutraceutical to Combat Post-Lyme Disease Syndrome
A Phase 2 study, sponsored by Optimal Health Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT04141969: Completed Phase 2 study, sponsored by Optimal Health Research.
NCT04141969 is a Phase 2 study that has completed, run by Optimal Health Research. The registered enrollment target is 100 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (25% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04141969, a Phase 2 study, has completed, sponsored by Optimal Health Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
This study will determine the effectiveness of a nutraceutical in treating the lingering effects of Lyme Disease after antibiotic treatment.
Primary Outcome
PROMIS Global-10; Self reported level changes as measured by the Patient-Reported Outcomes Measurement Information System Global-10 .
Interventions
- OTHER Placebo
- DIETARY_SUPPLEMENT RLP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2019-11-29 |
| Est. Completion | 2021-03-28 |
| Phase | Phase 2 |
What the finished NCT04141969 record still lists
NCT04141969 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (25% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04141969 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04141969 about?
NCT04141969 is a clinical study titled "A Novel Nutraceutical to Combat Post-Lyme Disease Syndrome". This study will determine the effectiveness of a nutraceutical in treating the lingering effects of Lyme Disease after antibiotic treatment.
What is the current status of trial NCT04141969?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2019-11-29. Estimated completion is 2021-03-28.
What interventions are being tested in trial NCT04141969?
The interventions under investigation include: Placebo (OTHER), RLP (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04141969?
This trial is sponsored by Optimal Health Research, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04141969's enrollment target sits among peer trials
100 672nd of 2000 higher than 1,263 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI